medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2019, Number 1

<< Back Next >>

Ann Hepatol 2019; 18 (1)

HLA Class II-DRB1 Alleles with Hepatitis C Virus Infection Outcome in Egypt: A Multicentre Family-based Study

El-Bendary M, Neamatallah M, Elalfy H, Besheer T, Kamel E, Mousa H, Eladl Abdel-Hamid, El-Setouhy M, El-Gilany Abdel-Hady, El-Waseef A, Esmat G

Language: English
References: 51
Page: 68-77
PDF size: 776.25 Kb.


ABSTRACT

Introduction and aim. Hepatitis C virus (HCV) infection is a global medical problem. HLA –DRB1 alleles have an important role in immune response against HCV. The aim of this study is to clarify the contribution of HLA –DRB1 alleles in HCV susceptibility in a multicentre family-based study. Material and methods. A total of 162 Egyptian families were recruited in this study with a total of 951 individuals (255 with chronic hepatitis C (CHC), 588 persons in the control group(-ve household contact to HCV) and 108 persons who spontaneously cleared the virus (SVC). All subjects were genotyped for HLA -DRB1 alleles by SSP-PCR and sequence based typing (SBT) methods. Results. The carriage of alleles 3:01:01 and 13:01:01 were highly significant in CHC when compared to that of control and SVC groups [OR of 3 family = 5.1289, Pc (Bonferroni correction ) = 0.0002 and 5.9847, Pc = 0.0001 and OR of 13 family = 4.6860, Pc = 0.0002 and OR = 6.5987, Pc = 0.0001 respectively]. While DRB1*040501, DRB1*040101, DRB1*7:01:01 and DRB1*110101 alleles were more frequent in SVC group than CHC patients (OR = 0.4052, Pc = 0.03, OR: OR = 0.0916, Pc = 0.0006, OR = 0.1833, Pc = 0.0006 and OR = 0.4061, Pc = 0.0001 respectively). Conclusions. It was concluded that among the Egyptian families, HLA- DRB1*030101, and DRB1*130101 alleles associated with the risk of progression to CHC infection, while DRB1*040101, DRB1*040501, DRB1*7:01:01and DRB1*110101 act as protective alleles against HCV infection.


REFERENCES

  1. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes, E. Global Distribution and Prevalence of Hepatitis C Virus Genotypes. Hepatology (Baltimore, Md) 2015; 61: 77-87.

  2. El-Shabrawi MH, Kamal NM. Burden of pediatric hepatitis C. World J Gastroenterol 2013; 19: 7880-8.

  3. Yee LJ. Host genetic determinants in hepatitis C virus infection. Genes Immun 2004; 5: 237-45.

  4. El-Bendary M, Esmat G, Neamatallah M, Kamel E, Besheer T, Elalfy H, El-Setouhy M, et al. Epidemiological Aspects of Intrafamilial Spread of HCV Infection in Egyptian Population: A Pilot Study. Open J Gastroenterol 2014; 4: 228-36.

  5. Urabe Y, Ochi H, Kato N, Kumar V, Takahashi A, Muroyama R, Hosono N, et al. A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region. J Hepatol 2013; 58: 875-82.

  6. Kamal SM, Kassim SK, Ahmed AI, Mahmoud S, Bahnasy KA, Hafez TA, Aziz IA, et al. Host and Viral Determinants of the Outcome of Exposure to HCV Infection Genotype 4: A Large Longitudinal Study. Am J Gastroenterol 2014; 109: 199-211.

  7. Bruno R, Sacchi P, Maiocchi L, Zocchetti C, Filice G. Host factors affecting the outcome of treatment of hepatitis C. Rev Gastroenterol Disord 2004; 4(Suppl. 1): S3-7.

  8. Tripathy AS, Shankarkumar U, Chadha MS, Ghosh K, Arankalle VA. Association of HLA alleles with hepatitis C infection in Maharashtra, western India. Indian J Med Res 2009; 130: 550-5.

  9. El-Bendary M, Neamatallah M, Esmat G, Kamel E, Elalfy H, Besheer T, Eldeib D, et al. Associations of human leucocyte antigen class II-DQB1 alleles with hepatitis C virus infection in Egyptian population: a multicentre family-based study. Journal of Viral Hepatitis 2016; 23: 961-70.

  10. Shaker O, Bassiony H, El Raziky M, El-Kamary S, Esmat G, El- Ghor AM, Mohamed M. Human Leukocyte Antigen Class II Alleles (DQB1 and DRB1) as Predictors for Response to Interferon Therapy in HCV Genotype 4. Mediat Inflamm 2013: 1-10.

  11. Thio CL, Thomas DL, Goedert JJ, Vlahov D, Nelson KE, Hilgartner MW, O’Brien SJ, et al. Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis 2001; 184: 16-21.

  12. Perneger TV. What’s wrong with Bonferroni adjustments. BMJ 1998; 316: 1236-8.

  13. Alric L, Fort M, Izopet J, Vinel JP, Charlet JP, Selves J, Puel J, et al. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology 1997; 113: 1675-81.

  14. Roulot D, Bourcier V, Grando V, Deny P, Baazia Y, Fontaine H, Bailly F, et al. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007; 14: 460-7.

  15. Gad RR, Males S, El Makhzangy H, Shouman S, Hasan A, Attala M, El Hoseiny M, et al. Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. Liver Int 2008; 28: 1112-9.

  16. Mahapatra C, Tripathy AS. Antigen Specific Cellular Response in Patients with Hepatitis C Virus Infection and its Association with HLA Alleles. IJCRIMPH 3.3 (2011): 273- 273.

  17. Lombard Z, Brune AE, Hoal EG, Babb C, Van Helden PD, Epplen JT, Bornman L. HLA class II disease associations in southern Africa. Tissue Antigens 2006; 67: 97-110.

  18. De Re V, Caggiari L, Monti G, Libra M, Spina M, Dolcetti R, De Zorzi M, et al. HLA DR-DQ combination associated with the increased risk of developing human HCV positive non-Hodgkin’s lymphoma is related to the type II mixed cryoglobulinemia. Tissue Antigens 2010; 75: 127-35.

  19. Singh R, Kaul R, Kaul A, Khan K. A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroenterol 2007; 13: 1770-87.

  20. Sim H, Wojcik J, Margulies M, Wade JA, Heathcote J. Response to interferon therapy: influence of human leucocyte antigen alleles in patients with chronic hepatitis C. J Viral Hepat 1998; 5: 249-53.

  21. Wang JH, Zheng X, Ke X, Dorak MT, Shen J, Boodram B, O’Gorman M, et al. Ethnic and geographical differences in HLA associations with the outcome of hepatitis C virus infection. Virol J 2009; 6: 46.

  22. Kuniholm MH, Kovacs A, Gao XJ, Xue XN, Marti D, Thio CL, Peters MG, et al. Specific Human Leukocyte Antigen Class I and II Alleles Associated with Hepatitis C Virus Viremia. Hepatology (Baltimore, Md) 2010; 51: 1514-22.

  23. McKiernan SM, Hagan R, Curry M, McDonald GS, Nolan N, Crowley J, Hegarty J, et al. The MHC is a major determinant of viral status, but not fibrotic stage, in individuals infected with hepatitis C. Gastroenterology 2000; 118: 1124-30.

  24. Vejbaesya S, Songsivilai S, Tanwandee T, Rachaibun S, Chantangpol R, Dharakul T. HLA association with hepatitis C virus infection. Hum Immunol 2000; 61: 348-53.

  25. Hue S, Cacoub P, Renou C, Halfon P, Thibault V, Charlotte F, Picon M, et al. Human leukocyte antigen class II alleles may contribute to the severity of hepatitis C virus-related liver disease. J Infect Dis 2002; 186: 106-9.

  26. McKiernan SM, Hagan R, Curry M, McDonald GS, Kelly A, Nolan N, Walsh A, et al. Distinct MHC class I and II alleles are as sociated with hepatitis C viral clearance, originating from a single source. Hepatology (Baltimore, Md) 2004; 40: 108-14.

  27. Romero-Gomez M, Gonzalez-Escribano MF, Torres B, Barroso N, Montes-Cano MA, Sanchez-Munoz D, Nunez-Roldan A, et al. HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C. Am J Gastroenterol 2003; 98: 1621-6.

  28. Minton EJ, Smillie D, Neal KR, Irving WL, Underwood JCE, James V, Trent Hepatitis C Virus Study Grp. Association between MHC class II alleles and clearance of circulating hepatitis C virus. J Infect Dis 1998; 178: 39-44.

  29. Thursz M, Yallop R, Goldin R, Trepo C, Thomas HC, Grp H. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. Lancet 1999; 354: 2119-24.

  30. Lopez-Vazquez A, Rodrigo L, Mina-Blanco A, Martinez-Borra J, Fuentes D, Rodriguez M, Perez R, et al. Extended human leukocyte antigen haplotype EH18.1 influences progression to hepatocellular carcinoma in patients with hepatitis C virus infection. J Infect Dis 2004; 189: 957-63.

  31. Kuzushita N, Hayashi N, Moribe T, Katayama K, Kanto T, Nakatani S, Kaneshige T, et al. Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus. Hepatology (Baltimore, Md) 1998; 27: 240-4.

  32. Kallinowski B, Scherer S, Mehrabi A, Theilmann L, Stremmel W. Clinical impact of HLA DR B1 genotypes in chronic hepatitis C virus infection. Transplantation proceedings 1999; 31: 3346-49.

  33. Tillmann HL, Chen DF, Trautwein C, Kliem V, Grundey A, Berning-Haag A, Boker K, et al. Low frequency of HLADRB1* 11 in hepatitis C virus induced end stage liver disease. Gut 2001; 48: 714-8.

  34. Yenigun A, Durupinar B. Decreased frequency of the HLADRB1* 11 allele in patients with chronic hepatitis C virus infection. J Virol 2002; 76: 1787-9.

  35. Fanning LJ, Levis J, Kenny-Walsh E, Wynne F, Whelton M, Shanahan F. Viral clearance in hepatitis C (1b) infection: relationship with human leukocyte antigen class II in a homogeneous population. Hepatology (Baltimore, Md) 2000; 31: 1334-7.

  36. Alric L, Izopet J, Fort M, Vinel J-P, Fontenelle P, Orfila C, Payen J-L, et al. Study of the association between major histocompatibility complex class II genes and the response to interferon alpha in patients with chronic hepatitis C infection. Hum Immunol 1999; 60: 516-23.

  37. Asti M, Martinetti M, Zavaglia C, Cuccia MC, Gusberti L, Tinelli C, Cividini A, et al. Human leukocyte antigen class II and III alleles and severity of hepatitis C virus-related chronic liver disease. Hepatology (Baltimore, Md) 1999; 29: 1272-9.

  38. Hong X, Yu R-B, Sun N-X, Wang B, Xu Y-C, Wu G-L. Human leukocyte antigen class II DQB1* 0301, DRB1* 1101 alleles and spontaneous clearance of hepatitis C virus infection: a meta-analysis. World J Gastroenterol 2005; 11: 7302-7.

  39. Corghi DB, Goncales NS, Marques SB, Goncales Jr FL. Distribution of the human leukocyte antigen class II alleles in Brazilian patients with chronic hepatitis C virus infection. Braz J Med Biol Res 2008; 41: 884-9.

  40. Cangussu LOF, Teixeira R, Campos EF, Rampim GF, Mingoti SA, Martins OA, Gerbase-DeLima M. HLA Class II Alleles and Chronic Hepatitis C Virus Infection. Scand J Immunol 2011; 74: 282-7.

  41. Ali L, Mansoor A, Ahmad N, Siddiqi S, Mazhar K, Muazzam AG, Qamar R, et al. Patient HLA-DRB1* and -DQB1* allele and haplotype association with hepatitis C virus persistence and clearance. J Gen Virol 2010; 91: 1931-8.

  42. Samimi-Rad K, Sadeghi F, Amirzargar A, Eshraghian MR, Alavian SM, Rahimnia R. Association of HLA class II alleles with hepatitis C virus clearance and persistence in thalassemia patients from Iran. J Med Virol 2015; 87: 1565-72.

  43. Hasan A-RS, Al-Ajeeli KSA. Association of Hepatitis C Virus (HCV) Infection and Human Leukocyte Antigens (HLA). Diyala Journal of Medicine 2: 53-9.

  44. Shaala A, Harfoush R, ElKhouly E, Ahmed M, Morsi M. Could Human Leukocyte Antigens (HLA) be Predictive Factors to Interferon Response among Chronic Hepatitis C Virus Hepatitis? J Med Microbiol Diagnos 2012; S1: 003. DOI:10.4172/ 2161-0703.S1-003

  45. Yosry A, Fouad R, Mahmoud S, El-Raziky MS, El-Hennawy A, Ghoneim MA. The association of HLA class II DR B1 alleles with HCV infection in Egyptian children. Arab J Gatroenterol 2011; 12: 25-8.

  46. Shankarkumar A, Shankarkumar U. HCV infection and its association with HLA alleles. International Journal of Life Sciences Biotechnology and Pharma Research 2012; 1: 10-9.

  47. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, Sun, Y, et al. Association between HLA-DRB1 alleles polymorphism and hepatocellular carcinoma: a meta-analysis. Bmc Gastroenterol 2010; 10: 145-55.

  48. Romero V, Azocar J, Zúñiga J, Clavijo OP, Terreros D, Gu X, Husain Z, et al. Interaction of NK inhibitory receptor genes with HLA-C and MHC class II alleles in Hepatitis C virus infection outcome. Molecular Immunology 2008; 45: 2429-36.

  49. Wawrzynowicz-Syczewska M, Underhill JA, Clare MA, Boron- Kaczmarska A, McFarlane IG, Donaldson PT. HLA class II genotypes associated with chronic hepatitis C virus infection and response to alpha-interferon treatment in Poland. Liver 2000; 20: 234-9.

  50. Yoon SK, Han JY, Pyo CW, Yang JM, Jang JW, Kim CW, Im Chang U, et al. Association between human leukocytes antigen alleles and chronic hepatitis C virus infection in the Korean population. Liver International 2005; 25: 1122-7.

  51. Ksiaa L, Ayed-Jendoubi S, Sfar I, Gorgi Y, Najjar HA, Abdallah TB, Ayed, K. Clearance and persistence of hepatitis C virus in a Tunisian population: association with HLA class I and class II. Viral Immunol 2007; 20: 312-9.




2020     |     www.medigraphic.com